A Brisbane biotech with a contrarian bet: the immune system in autoimmune disease isn't broken. It's confused. Stop suppressing it. Re-teach it.
Above: the Kira Biotech wordmark, photographed doing what wordmarks do - sitting very still while the science underneath moves slowly and expensively.
In a lab in Toowong, a handful of people are arguing with one of medicine's oldest assumptions - that to calm an overactive immune system, you have to turn the whole thing down.
Kira Biotech is small. Four people on the headcount, a single office in Brisbane, one molecule doing most of the talking. By the noisy standards of biotech press releases, that should make it forgettable. It isn't, because the idea it is chasing is one the field has wanted for forty years and mostly failed to deliver: immune tolerance.
The pitch is almost rude in its simplicity. Today's autoimmune drugs work like a dimmer switch on the entire immune system. They help - and then they leave patients more exposed to infection, and sometimes cancer, because a dialed-down immune system protects you less from everything. Kira's wager is that you don't need the dimmer. You need a scalpel.
Rheumatoid arthritis. Lupus. Type 1 diabetes. Graft-versus-host disease. Different names, same underlying betrayal: immune cells that are supposed to defend the body start attacking it instead. Millions live with this. The tools we have to treat them are, charitably, blunt.
Steroids, broad immunosuppressants, biologics that knock out whole cell populations - they manage symptoms while quietly raising the bill elsewhere. Patients trade joint pain for infection risk. They trade a flare for a vulnerability. It is the oldest deal in immunology, and nobody loves the terms.
The deeper problem is precision. The immune system contains the cells driving the disease and the cells keeping you alive, and they look, to most drugs, exactly the same. Hit one, you hit both. So the question Kira started with wasn't "how do we suppress harder?" It was "how do we tell them apart?"
Kira didn't start from a whiteboard. It started from decades of dendritic-cell research at Australian institutes - work carried in large part by the late Professor Derek Hart and Associate Professor Georgina Clark across the Mater Medical Research Institute, ANZAC Research Institute, and the University of Sydney. Dendritic cells are the immune system's switchboard operators: they decide what counts as a threat. Understand them, the thinking goes, and you can change the conversation the immune system is having with itself.
To turn lab science into a drug, the company recruited Dr Dan Baker as founding CEO - a US-based rheumatologist and immunologist who had done time at Janssen and knew the unglamorous machinery of getting a molecule through trials. Around him gathered pharma veterans, including a former Johnson & Johnson VP as board chair. An Australian discovery, an American drug developer, and a board that had shipped medicines before.
In October 2019, the bet got capital. A$20 million in Series A, led by OneVentures with significant backing from IP Group and the Advance Queensland Business Development Fund. Not a fortune by global biotech standards. Enough to find out if the idea survives contact with a human trial.
Dendritic-cell research by Professor Derek Hart and A/Prof Georgina Clark builds the foundation across Sydney and Brisbane institutes.
OneVentures leads, with IP Group and the Advance Queensland Business Development Fund. Dr Dan Baker named founding CEO.
The first-in-class, selective immune-cell depleting antibody is positioned for preclinical and early clinical development.
The team adds experienced pharma executives to steer the company toward the clinic.
Business development capability deepens as Kira prepares to translate science into partnerships.
KB312 is a monoclonal antibody with one job described in three careful words: first-in-class, selective, depleting. It seeks out activated immune cells - the ones driving the attack - and removes them, while leaving the rest of the immune system intact. The goal isn't suppression. It's restoring homeostasis: nudging the system back toward tolerating the body it lives in.
The distinction matters more than it sounds. A blanket immunosuppressant lowers the volume on everything. KB312 is meant to mute one instrument in the orchestra and let the rest keep playing - so patients keep the immune defenses that protect them against infection and cancer. If it works, that's the difference between a drug you fear and a drug you can live with.
Targets activated immune cells, not the whole population, to induce tolerance rather than broad suppression.
A monoclonal antibody with no direct predecessor doing exactly this job in exactly this way.
Spares the immune cells that guard against infection and malignancy - the cells most drugs sacrifice.
Honesty section. Kira is early. There is no approved drug, no revenue line worth framing, no blockbuster yet. What there is: capital, a credible scientific lineage, investors who do this for a living, and a target list of diseases big enough to matter. The chart below is small on purpose - this is a company measured in conviction and runway, not yet in sales.
A lean team and a single molecule against a five-disease wishlist. Biotech math: the odds are long, the upside is a category.
The backers are the strongest external signal. OneVentures and IP Group don't write checks for vibes; they fund science they think can clear a regulator. The Queensland government put public money behind it too. None of that guarantees KB312 works. All of it means serious people looked at the data and decided it was worth the risk.
"KB312 is an example of an Australian technology that has potential for global health impact with its differentiated treatment approach."- Associate Professor Georgina Clark, Co-Founder & Director
Kira's stated mission is unfashionably plain: advance immunology drug development by building therapies that restore immune tolerance instead of suppressing the immune system. No moonshot language. Just a clear sentence about a hard problem.
Immune tolerance has been called the holy grail of autoimmunity for a reason - lots of people have chased it, few have caught it. The biology is genuinely difficult, and the graveyard of tolerance programs is well populated. Kira knows this. The company's entire structure - small team, focused pipeline, patient capital, pharma-grade leadership - reads like a group that has decided to do one thing carefully rather than five things loudly.
Ultimately, patients - the people living with diseases that today's medicine manages rather than resolves. Nearer term, the audience is the clinical and regulatory machine, and the pharma partners who might one day carry KB312 the rest of the way. Kira is not building a consumer brand. It's building a piece of science other people will need.
Run the idea forward. If a selective, tolerance-inducing antibody works in even one autoimmune disease, the template travels. The same logic - find the activated cells, remove them, leave the rest - could apply across a family of conditions that currently share the same unsatisfying treatment menu. That's not one drug. That's a way of thinking about an entire field.
And if it doesn't work? Then a small Brisbane team will have tested one of immunology's most important hypotheses with real money and real rigor, and the field learns from the attempt. That is how this science moves - not in single leaps, but in well-funded, well-run swings at hard targets.
Back to that lab in Toowong. The argument they're having with forty years of assumption is still unresolved. But it's funded, it's staffed by people who've done this before, and it's pointed at a question worth answering. The immune system, in autoimmune disease, isn't broken. Kira Biotech is betting it can be talked back into reason. We'll find out in the clinic - which is the only place that opinion has ever counted.
Profile compiled from public sources: company website, investor and institutional announcements, and press coverage. Figures (funding, team size, indications) reflect publicly reported information from 2019-2021 and may have changed. Approximate where noted. No affiliation or endorsement implied.